Adverum Biotechnologies, Inc. (ADVM)
NASDAQ: ADVM · Real-Time Price · USD
2.850
-0.110 (-3.72%)
Apr 23, 2025, 11:59 AM EDT - Market open

Adverum Biotechnologies Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Revenue
13.6-7.5-
Upgrade
Revenue Growth (YoY)
-72.22%----
Upgrade
Cost of Revenue
77.0477.4995.5889.1873.31
Upgrade
Gross Profit
-76.04-73.89-95.58-81.68-73.31
Upgrade
Selling, General & Admin
63.1255.0654.7363.3844.64
Upgrade
Operating Expenses
63.1255.0654.7363.3844.64
Upgrade
Operating Income
-139.16-128.94-150.31-145.06-117.95
Upgrade
Interest & Investment Income
8.235.752.670.581.56
Upgrade
EBT Excluding Unusual Items
-130.93-123.19-147.64-144.48-116.39
Upgrade
Merger & Restructuring Charges
---4.7--
Upgrade
Asset Writedown
---2.12-1.06-
Upgrade
Pretax Income
-130.93-123.19-154.46-145.54-116.39
Upgrade
Income Tax Expense
--1.080.07-1.11
Upgrade
Net Income
-130.93-122.12-154.54-145.54-117.51
Upgrade
Net Income to Common
-130.93-122.12-154.54-145.54-117.51
Upgrade
Shares Outstanding (Basic)
201010109
Upgrade
Shares Outstanding (Diluted)
201010109
Upgrade
Shares Change (YoY)
96.21%1.58%1.24%15.14%32.83%
Upgrade
EPS (Basic)
-6.62-12.11-15.57-14.85-13.80
Upgrade
EPS (Diluted)
-6.62-12.11-15.57-14.85-13.80
Upgrade
Free Cash Flow
-92.85-91.71-119.91-122.95-91.14
Upgrade
Free Cash Flow Per Share
-4.69-9.10-12.08-12.54-10.70
Upgrade
Operating Margin
-13915.90%-3581.72%--1934.12%-
Upgrade
Profit Margin
-13092.70%-3392.11%--1940.53%-
Upgrade
Free Cash Flow Margin
-9285.00%-2547.50%--1639.39%-
Upgrade
EBITDA
-135.51-123.3-143.78-140.41-113.79
Upgrade
D&A For EBITDA
3.655.646.534.654.16
Upgrade
EBIT
-139.16-128.94-150.31-145.06-117.95
Upgrade
Updated Apr 15, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q